Scinopharm Taiwan, Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2019
August 01, 2019 at 11:16 pm
Share
ScinoPharm Taiwan, Ltd. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced sales was TWD 617.573 million compared to TWD 985.607 million a year ago. Operating income was TWD 61.596 million compared to TWD 159.854 million a year ago. Net income was TWD 57.139 million compared to TWD 131.078 million a year ago. Basic earnings per share was TWD 0.07 compared to TWD 0.17 a year ago. For the half year, sales was TWD 1,389.618 million compared to TWD 1,846.894 million a year ago. Operating income was TWD 179.020 million compared to TWD 281.303 million a year ago. Net income was TWD 135.600 million compared to TWD 266.600 million a year ago. Basic earnings per share was TWD 0.17 compared to TWD 0.34 a year ago.
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
SCINOPHARM TAIWAN, LTD. 
